Literature DB >> 20947690

Dynamic International Prognostic Scoring System (DIPSS) predicts progression to acute myeloid leukemia in primary myelofibrosis.

Francesco Passamonti, Francisco Cervantes, Alessandro Maria Vannucchi, Enrica Morra, Elisa Rumi, Mario Cazzola, Ayalew Tefferi.   

Abstract

Entities:  

Mesh：

Year:  2010        PMID： 20947690     DOI： 10.1182/blood-2010-06-293415

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  46 in total

1.  The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients.

Authors:  P Guglielmelli; T L Lasho; G Rotunno; J Score; C Mannarelli; A Pancrazzi; F Biamonte; A Pardanani; K Zoi; A Reiter; A Duncombe; T Fanelli; D Pietra; E Rumi; C Finke; N Gangat; R P Ketterling; R A Knudson; C A Hanson; A Bosi; A Pereira; R Manfredini; F Cervantes; G Barosi; M Cazzola; N C P Cross; A M Vannucchi; A Tefferi
Journal:  Leukemia       Date:  2014-02-19       Impact factor: 11.528

Review 2.  Role of hematopoietic stem cell transplantation in patients with myeloproliferative disease.

Authors:  Rachel B Salit; H Joachim Deeg
Journal:  Hematol Oncol Clin North Am       Date:  2014-10-03       Impact factor: 3.722

3.  Interferon Therapy in Myelofibrosis: Systematic Review and Meta-analysis.

Authors:  Jan Philipp Bewersdorf; Smith Giri; Rong Wang; Nikolai Podoltsev; Robert T Williams; Raajit K Rampal; Martin S Tallman; Amer M Zeidan; Maximilian Stahl
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2020-05-28

4.  Clinical use of ruxolitinib in an academic medical center in unselected patients with myeloproliferative neoplasms not on clinical study.

Authors:  Kiran Naqvi; Naval Daver; Naveen Pemmaraju; Prithviraj Bose; Guillermo Garcia-Manero; Jorge Cortes; Hagop M Kantarjian; Srdan Verstovsek
Journal:  Leuk Lymphoma       Date:  2016-08-05

5.  Distinct clustering of symptomatic burden among myeloproliferative neoplasm patients: retrospective assessment in 1470 patients.

Authors:  Holly L Geyer; Robyn M Scherber; Amylou C Dueck; Jean-Jacques Kiladjian; Zhijian Xiao; Stefanie Slot; Sonja Zweegman; Federico Sackmann; Ana Kerguelen Fuentes; Dolores Hernández-Maraver; Konstanze Döhner; Claire N Harrison; Deepti Radia; Pablo Muxi; Carlos Besses; Francisco Cervantes; Peter L Johansson; Bjorn Andreasson; Alessandro Rambaldi; Tiziano Barbui; Alessandro M Vannucchi; Francesco Passamonti; Jan Samuelsson; Gunnar Birgegard; Ruben A Mesa
Journal:  Blood       Date:  2014-02-19       Impact factor: 22.113

6.  Platelet expression of PKCepsilon oncoprotein in myelofibrosis is associated with disease severity and thrombotic risk.

Authors:  Elena Masselli; Cecilia Carubbi; Giulia Pozzi; Silvia Martini; Franco Aversa; Daniela Galli; Giuliana Gobbi; Prisco Mirandola; Marco Vitale
Journal:  Ann Transl Med       Date:  2017-07

7.  Discrepancies of applying primary myelofibrosis prognostic scores for patients with post polycythemia vera/essential thrombocytosis myelofibrosis.

Authors:  Krisstina Gowin; Maria Coakley; Heidi Kosiorek; Ruben Mesa
Journal:  Haematologica       Date:  2016-06-27       Impact factor: 9.941

8.  The impact of anemia on overall survival in patients with myelofibrosis treated with ruxolitinib in the COMFORT studies.

Authors:  Vikas Gupta; Claire Harrison; Elizabeth O Hexner; Haifa Kathrin Al-Ali; Lynda Foltz; Michael Montgomery; William Sun; Prashanth Gopalakrishna; Hagop Kantarjian; Srdan Verstovsek
Journal:  Haematologica       Date:  2016-09-01       Impact factor: 9.941

Review 9.  Prognosis of Primary Myelofibrosis in the Genomic Era.

Authors:  Prithviraj Bose; Srdan Verstovsek
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2016-08

10.  Prognostic implications and clinical characteristics associated with bone marrow fibrosis in patients with myelofibrosis.

Authors:  Aziz Nazha; Zeev Estrov; Jorge Cortes; Carlos E Bueso-Ramos; Hagop Kantarjian; Srdan Verstovsek
Journal:  Leuk Lymphoma       Date:  2013-02-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.